Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction - Wikidata - awgldk - TriplyDB

Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction

Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction

http://www.wikidata.org/entity/Q33855337

about

Adrenal G protein-coupled receptor kinase-2 in regulation of sympathetic nervous system activity in heart failure G-protein-coupled receptor kinases in inflammation and disease Risk of acute myocardial infarction after transurethral resection of prostate in elderly The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development.G protein-coupled Receptor Kinase 2 as a Therapeutic Target for Heart Failure.GRK2 Up-Regulation Creates a Positive Feedback Loop for Catecholamine Production in Chromaffin Cells.β-Adrenergic receptor subtype signaling in heart: from bench to bedside.A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse.Targeting G protein-coupled receptor kinases (GRKs) in Heart Failure.Impaired desensitization of a human polymorphic α2B-adrenergic receptor variant enhances its sympatho-inhibitory activity in chromaffin cells.G protein coupled receptor kinases as therapeutic targets in cardiovascular disease.GRK2 and β-arrestins in cardiovascular disease: Something old, something new.Gi-biased β2AR signaling links GRK2 upregulation to heart failure.The evolving impact of g protein-coupled receptor kinases in cardiac health and disease Myocardial β(2) -adrenoceptor gene delivery promotes coordinated cardiac adaptive remodelling and angiogenesis in heart failure.Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failure Impact of diabetes on cardiac sympathetic innervation in patients with heart failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study Effect of heart failure on catecholamine granule morphology and storage in chromaffin cells GRK 2 level in peripheral blood lymphocytes of elderly patients with acute myocardial infarction Current and future G protein-coupled receptor signaling targets for heart failure therapy Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction.Adrenergic nervous system in heart failure: pathophysiology and therapy.Neuro-hormonal effects of physical activity in the elderly.Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms.β- and α2-Adrenoceptor Control of Vascular Tension and Catecholamine Release in Female Normotensive and Spontaneously Hypertensive Rats.GRK2 as a novel gene therapy target in heart failure.Taking the heart failure battle inside the cell: small molecule targeting of Gβγ subunits Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.G protein-coupled receptor kinases in normal and failing myocardium.Are the pharmacology and physiology of α₂ adrenoceptors determined by α₂-heteroreceptors and autoreceptors respectively?Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade.G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms.Molecular aspects of the cardioprotective effect of exercise in the elderly.Physiology and pharmacology of the cardiovascular adrenergic system.Adrenal adrenoceptors in heart failure.Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling.β1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy Serotonin and Serotonin Transporters in the Adrenal Medulla: A Potential Hub for Modulation of the Sympathetic Stress Response.Targeting GPCR-Gβγ-GRK2 signaling as a novel strategy for treating cardiorenal pathologies.Kinetic Isotope Effects and Transition State Structure for Human Phenylethanolamine N-Methyltransferase.

P2860

Q26785936-A819566A-E6D2-49FF-8AF2-F19461A6B5BA Q26801467-528D6A81-3DC7-49EF-988D-163DA4FD99FD Q26859700-92DEEE87-A272-4E2E-9ACE-7D902A044669 Q30250314-A2E2FEF1-2D87-4057-9934-C31968241BFD Q33604042-BE73ED6B-7C63-4809-97EA-A0A571626A87 Q33631406-29342F7C-F547-4207-A7DD-A826953D7CA3 Q33828730-975B34CC-1DE6-4E2F-A32D-651E98B695CF Q34423842-EDF0F757-7D58-4E5A-B447-219790608F67 Q34460199-2AE85DE8-EFAA-4661-BB75-B150E54D1A3E Q34586312-0B78658F-A208-48AF-A48E-4623DC164652 Q35135090-B2293D54-38DB-42CE-A234-BDCBEAFE6B1B Q35660111-CAA4DE0F-F883-45A6-B6EE-BAF9E41E0BDF Q35766985-42EB3812-438F-4B3E-984F-015785C7B0EB Q36000382-1F9F8693-A1FF-4660-984A-2956045FD220 Q36252791-523A01E7-66A7-4CEE-B566-967D157FAAAF Q36252811-0CF3E2CB-BE02-4BB6-BF79-FA193450547E Q37022630-D2296EB0-48B4-4301-BC1C-481A2F570658 Q37165787-BF5C6E78-4A8C-4EB0-A0EC-9F17C504E6DD Q37229933-0A750C92-BB92-4689-9274-BFA577841DD6 Q37232104-221BC4B7-FD3B-4838-9365-42D8062C25E2 Q37265891-635BD70B-698B-4622-BDDE-CC416ABAB6B3 Q37349756-E4E323B1-C07B-4023-9E13-336394327DC5 Q37404953-0AD5A050-05FE-42A6-B562-34E7AF392801 Q37470858-7407F57C-6B0A-4032-9C5D-B43F2850D511 Q37737632-0A11CAD9-769F-4487-8F73-9A08A7AB292E Q37783642-8883A154-12C5-4EB1-96D3-FA92A353E84E Q37831634-7DE4AF22-34E6-4664-9EA2-A1F17EC7132C Q37833892-8F2741EE-AC83-4CF9-877D-50F0A6BFE937 Q37881660-2BB736A8-B058-4E8B-BAC6-06C73CDA6361 Q37887038-CD7AA39B-485B-4D8D-A077-7329DF841C45 Q37984182-06C9A01C-890B-4F1D-9717-D29D73A46B92 Q38093493-6BCF0B7D-CC04-4BA2-800F-25379F270D68 Q38129354-A9C7224A-0248-42DB-9884-CE9DF3CE7CBF Q38136643-52C64DAD-A054-4F28-A00D-8E49E0166ED2 Q38234911-C70DA909-2652-479E-B051-44B33CB734D8 Q38256143-D1E3F3F0-1E2D-46B4-B19E-FBFBC2CE7C3E Q38266154-FDDD5084-D8E0-4DEB-AA9A-2FB150F59CD7 Q38431920-10AE6D24-B353-4030-898F-94B979C21E3A Q39107039-2DBB647C-09FB-4193-BC13-96A52B99ED0C Q41358452-D99D7717-D39D-49F7-836F-ACCC56B9F9D1

P2860

Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction

http://www.wikidata.org/entity/Q33855337

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Reduction of sympathetic activ ...... on after myocardial infarction

@ast

Reduction of sympathetic activ ...... on after myocardial infarction

@en

type

label

Reduction of sympathetic activ ...... on after myocardial infarction

@ast

Reduction of sympathetic activ ...... on after myocardial infarction

@en

prefLabel

Reduction of sympathetic activ ...... on after myocardial infarction

@ast

Reduction of sympathetic activ ...... on after myocardial infarction

@en

P1433

Q33855337-E31FD6F2-593E-4C15-B61C-52D4929F8745

P1476

Q33855337-DD84EDD2-652F-42B9-8067-B7594BB635C6

P2093

Q33855337-0825F56D-49C2-42C8-8761-DDBD268903E6

Q33855337-8B941F1D-388E-4ACC-96F7-5EA90E5530D4

Q33855337-AEAA14B8-549F-48AF-9B96-7B01883CE407

P2860

Q33855337-005F8B7C-5D03-4C32-97B0-772D9D6E3A35

Q33855337-00740C7F-BA00-48FB-9F9F-8C02772AB8EE

Q33855337-08695BC7-3378-488E-8132-58902D0DB51C

Q33855337-0F42F4E9-5AF4-453D-BDEB-52A09C5F3370

Q33855337-1955E0D9-6120-4320-A403-8FDF985340AC

Q33855337-1E23BA65-DB9E-4A64-96A2-700AC4757FC7

Q33855337-24F6435C-B4FC-4445-9FDF-60C65BFD3730

Q33855337-2A30A7C4-7B8F-4F03-8178-1898E7EB863B

Q33855337-2E7622C1-51F4-45F8-ADD9-B8BE5E8A932A

Q33855337-3EA784B3-7171-44DA-A0EB-169FA01741E5

P304

Q33855337-69372825-79F1-40A9-B2CC-61B259043B2C

P31

Q33855337-93D650AB-444D-428C-9C4A-7619068538D5

P356

Q33855337-595B064F-D356-4ABB-85E4-6A874B8FCA99

P407

Q33855337-71914E4E-64C0-48FF-96F5-28974D191C04

P433

Q33855337-044676B2-FA3A-41AC-8784-1B6CDDF86C84

P478

Q33855337-747A1791-B35F-46AE-B4FB-65FA27DB4BE9

P50

Q33855337-085C9240-9175-45CC-94FF-A22F3539FA26

Q33855337-1F79BDEE-BF55-4D6B-AE2F-5A72A6072B1D

Q33855337-2E21127B-9842-445F-B2F0-4F77F440DCEF

P577

Q33855337-40738B5C-662E-4874-822A-DD4D38C0C0F7

P698

Q33855337-D2CF4C08-75BC-4A8C-A1D1-AC390B874A5F

P921

Q33855337-600CE3B0-B951-4EF1-8D2C-98EE70626751

Q33855337-75059273-F7C7-4206-948F-B0B38A5FE847

P932

Q33855337-A27763CB-B935-43FB-A73E-F76E158D6F21

P356

JBC.M109.077859

P1433

Journal of Biological Chemistry

P1476

Reduction of sympathetic activ ...... on after myocardial infarction

@en

P2093

Gerald W Dorn

http://www.w3.org/2001/XMLSchema#string

Steven N Ebert

http://www.w3.org/2001/XMLSchema#string

Walter J Koch

http://www.w3.org/2001/XMLSchema#string

P2860

Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine

Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure

Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor

Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity

Conditional mouse models to study developmental and pathophysiological gene function in muscle.

G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure.

Epidemiology, pathophysiology, and prognosis of heart failure in the elderly.

Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission.

Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure.

Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure.

P304

16378-16386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M109.077859

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

285

http://www.w3.org/2001/XMLSchema#string

P50

Anastasios Lymperopoulos

P577

2010-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20351116

http://www.w3.org/2001/XMLSchema#string

P921

P932

2871505

http://www.w3.org/2001/XMLSchema#string